Skip to content

ALDEYRA THERAPEUTICS, INC.: 10-Q filed 2016-08-10

What ALDEYRA THERAPEUTICS, INC. reported in its quarterly report filed 2016-08-10 (fiscal Q2 2016): 26 published measures, 67 facts as tagged in accession 0001193125-16-677524.

This filing

Form
10-Q (quarterly report)
Filed
2016-08-10
Fiscal period
fiscal Q2 2016
Accession
0001193125-16-677524 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ALDEYRA THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2016-06-3032,883,548USD
At 2015-12-3128,204,764USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2016-06-303,365,824USD
At 2015-12-313,326,445USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2016-06-3029,517,724USD
At 2015-12-3124,878,319USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2016-06-3017,607,522USD
At 2015-12-3114,648,866USD
At 2015-06-3033,569,784USD
At 2014-12-318,527,304USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-4,302,616USD91
2016-01-01 to 2016-06-30-9,269,969USD182
2015-04-01 to 2015-06-30-2,232,186USD91
2015-01-01 to 2015-06-30-4,368,745USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2016-01-01 to 2016-06-3011,810USD182
2015-01-01 to 2015-06-3031,876USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2016-06-30-67,871,854USD
At 2015-12-31-58,601,884USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2016-01-01 to 2016-06-300USD182

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2016-06-3075,027USD
At 2015-12-3180,334USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2016-01-01 to 2016-06-301,282,687USD182
2015-01-01 to 2015-06-301,103,661USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-4,296,750USD91
2016-01-01 to 2016-06-30-9,263,787USD182
2015-04-01 to 2015-06-30-2,203,976USD91
2015-01-01 to 2015-06-30-4,312,511USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2016-06-3032,808,521USD
At 2015-12-3128,088,194USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2016-04-01 to 2016-06-3027,817USD91
2016-01-01 to 2016-06-3052,853USD182
2015-04-01 to 2015-06-3028,210USD91
2015-01-01 to 2015-06-3056,234USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2016-06-302,373,199USD
At 2015-12-312,115,135USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2016-06-30823,301USD
At 2015-12-31851,160USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2016-04-01 to 2016-06-302,834,523USD91
2016-01-01 to 2016-06-306,346,037USD182
2015-04-01 to 2015-06-301,249,097USD91
2015-01-01 to 2015-06-302,385,531USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2016-06-3012,472,521shares
At 2015-12-319,712,521shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2016-06-304,703USD
At 2015-12-31-8,361USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2016-06-301,084,591USD
At 2015-12-311,186,429USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2016-06-30260,087USD
At 2015-12-31497,552USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-4,299,712USD91
2016-01-01 to 2016-06-30-9,256,905USD182
2015-04-01 to 2015-06-30-2,232,186USD91
2015-01-01 to 2015-06-30-4,368,745USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2016-04-01 to 2016-06-301,462,227USD91
2016-01-01 to 2016-06-302,917,750USD182
2015-04-01 to 2015-06-30954,879USD91
2015-01-01 to 2015-06-301,926,980USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2016-01-01 to 2016-06-3017,117USD182
2015-01-01 to 2015-06-304,002USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-5,866USD91
2016-01-01 to 2016-06-30-6,182USD182
2015-04-01 to 2015-06-30-28,210USD91
2015-01-01 to 2015-06-30-56,234USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2016-01-01 to 2016-06-3012,768,745USD182
2015-01-01 to 2015-06-3028,520,046USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-06-30-27,859USD182
2015-01-01 to 2015-06-30288,052USD181

Inspect the source

Entity
ALDEYRA THERAPEUTICS, INC. / CIK 0001341235
Captured
2026-09-20T07:54:15.451Z
SEC response SHA-256
71cda24b59474759e40949f545ab949ecdfc2871814e3cf45050931d1c516763

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001341235.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))